Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by Dacoltson Dec 16, 2004 4:01pm
112 Views
Post# 8324456

Resverlogix arranges $3.08-million bought dea

Resverlogix arranges $3.08-million bought deaResverlogix arranges $3.08-million bought deal 2004-12-16 15:38 ET - News Release Mr. Donald McCaffrey reports RESVERLOGIX CORP. ANNOUNCES $3.08 MILLION BOUGHT DEAL Resverlogix Corp. has entered into an agreement with First Associates Investments Inc. (FAII under which the remaining 1,027,033 common shares available for purchase under Resverlogix's previously announced private placement offering of up to 3.67 million common shares will be offered at $3 per share (reflecting a continuation of the previously established offering price) by FAII and its syndicate, comprising Haywood Securities Inc., Loewen Ondaatje McCutcheon Ltd., Sprott Securities Inc. and Jennings Capital Inc., on a bought-deal basis. The initial 2,639,633 common shares were issued on Nov. 23, 2004. Previously the terms for the offering provided for a best-efforts basis offering and the syndicate has now been revised as reflected above. The proposed private placement will be offered through the underwriters pursuant to applicable prospectus exemptions in Canada. We seek Safe Harbor.
Bullboard Posts